Biotech and med-tech sectors are witnessing leadership transitions and funding activity amid evolving market conditions. Notable appointments include executives at Thermo Fisher, Agilent, Llusern Scientific, and Bristol Myers Squibb’s new CMO. Investment highlights comprise Leads Biolabs nearly doubling its valuation post Hong Kong IPO, Brandon Capital closing a record AU$439M life sciences fund, and various companies progressing Series B rounds. Despite market challenges, investors remain selectively bullish, focusing on clinical-stage biopharma and mature technologies.